Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases

Annals of Gastroenterology

Volumn 27, Issue 2, 2014, Pages 179-180

  Rezaie, Ali ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHOTREXATE; PLACEBO; STEROID; VEDOLIZUMAB;

BIOLOGICAL THERAPY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; NOTE; REMISSION; TREATMENT FAILURE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84897102224     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
2. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
3. Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996-1006.
4. Sandborn WJ. The future of inflammatory bowel disease therapy: where do we go from here? Dig Dis 2012;30(Suppl 3):140-144.
5. Jovani M, Danese S. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets 2013;14:1433-1443.